Description

VNP20009 is a very effective anti-cancer agent and can specifically target tumors and inhibit tumor growth. It was assumed that the tumor targeting ability of VNP20009 correlated to its anticancer

VNP20009 is a very effective anti-cancer agent and can specifically target tumors and inhibit tumor growth. It was assumed that the tumor targeting ability of VNP20009 correlated to its anticancer capacity. However, our observation contradicted to this assumption. Three VNP20009 mutant strains (ΔslyA, ΔSTM3120 and ΔhtrA) with reduced fitness in normal tissues and unchanged fitness in tumors partially or completely lost their anti-cancer capacities.

Reuse Permissions
  • application/pdf

    Download count: 0

    Details

    Contributors
    Date Created
    • 2016-11-08
    Resource Type
  • Text
  • Collections this item is in
    Identifier
    • Digital object identifier: 10.18632/oncotarget.13217
    • Identifier Type
      International standard serial number
      Identifier Value
      1949-2553
    Note

    Citation and reuse

    Cite this item

    This is a suggested citation. Consult the appropriate style guide for specific citation guidelines.

    Zhang, X., Xu, Q., Yang, L., Lai, Y., Zhang, Z., Han, C., . . . Hua, Z. (2016). The genes slyA, STM3120 and htrA are required for the anticancer ability of VNP20009. Oncotarget. doi:10.18632/oncotarget.13217

    Machine-readable links